End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10,450 KRW | +2.65% | +3.26% | +22.94% |
03-25 | Sihuan Pharmaceutical's RF Device Wins Registration Approval in China | MT |
2023 | SULLIVAN WILL DISCUSS EFFORTS TO REIN IN 'EXTREMIST SETTLER VIOL… | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm trades with high earnings multiples: 27.82 times its 2023 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.94% | 422M | - | ||
+4.93% | 213B | B | ||
+9.21% | 188B | B- | ||
+30.72% | 157B | B- | ||
+32.76% | 113B | A- | ||
+5.25% | 64.85B | A- | ||
+21.77% | 55.17B | B+ | ||
+1.34% | 49.1B | B+ | ||
-4.69% | 38.83B | A | ||
+1.66% | 35.6B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A335890 Stock
- Ratings VIOL Co., Ltd.